News

Aug 12, 2019 : ForteBio introduces high precision Octet system biosensor for process development rigor

August 12, 2019 - ForteBio, the Biologics Business Unit of Molecular Devices, announced today at Bioprocessing Summit in Boston, the release of the new High Precision Streptavidin 2.0 (SAX2) biosensor for the Octet® platform. Focused on meeting customers’ needs to minimize variability from consumables, the SAX2 biosensors are controlled to meet the most stringent of assay precision requirements with <4% CV within lots and <20% between lots.

Streptavidin biosensors are used for quick and easy customization of biosensors to make quantitative and kinetic measurements with any biotin-tagged molecule. By applying a higher level of precision with SAX2, this flexible capture method can be more readily developed and qualified in downstream and regulated applications, such as product release testing, activity assays in manufacturing, and more.

“The SAX2 biosensor rounds out our product and service offerings to our GxP customers, giving them fast and reliable tools from qualifying instruments to validating methods and maintaining data integrity,” said Laurent Claisse, General Manager for ForteBio.

Visit https://www.fortebio.com/SAX2 to learn more.

About Molecular Devices

Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

ForteBio is a business unit of Molecular Devices, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and automation and customization of engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development and manufacturing.

Contact Information:

Craig Tin
Director, Regional Marketing
1 650 289 6862
Craig.Tin@moldev.com

Jun 10, 2019 : Jubilant Biosys is first to add ForteBio's latest SPR System in India, for fragment screening and characterization of lead compounds

BENGALURU, KA, India and SAN JOSE, Calif., May 20, 2019 /PRNewswire/ -- Jubilant Biosys, a wholly owned subsidiary of Jubilant Life Sciences, announced today that it has recently added advanced Pioneer FE system to their platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio, the Biologics Business Unit of Molecular Devices, represents the next generation SPR instrumentation for label-free characterization of biomolecules. Sensitive enough to measure high affinity and covalent binding events, the Pioneer systems also uses a unique OneStep® gradient injection technology to facilitate fragment screening. Pioneer systems with OneStep technology can analyze up to 768 fragments in 24 hours, obtaining kinetics during the primary screen and eliminating the need for additional screens.

The Pioneer system is the first unit placed in India, and part of Jubilant's continuing investment in new technologies supporting their innovator customer needs. Said Marcel Velterop, President of Jubilant Biosys, "The addition of the Pioneer SPR system will significantly upgrade and speed up our small molecule hit-finding engine for novel target classes."

Greg Milosevich, President of Molecular Devices, commented, "We are pleased to have Jubilant adopt the Pioneer platform and look forward to supporting them and their customers' goals in fast-tracking small molecule drug discovery programs."

 

About Jubilant Biosys Limited

Jubilant Biosys, a subsidiary of Jubilant Life Sciences Ltd., an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise across multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. Business models include both functional and integrated discovery services up to IND including GLP and GMP services, proprietary in-house innovation and strategic investments as the core components which are available for collaborative research, partnership and out licensing.

 

About Molecular Devices, LLC

Molecular Devices, one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Within the broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and discovery of new therapeutics. Molecular Devices is committed to continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

 

Contact for Molecular Devices

Craig Tin Director, Regional Marketing 650-289-6862 Craig.Tin@moldev.com

 

Contact for Jubilant Biosys

Drishti Asthana Executive, Business Development Jubilant Chemsys Limited +919899033635 Drishti.Asthana@jchemsys.com

Mar 12, 2019 : ForteBio Introduces New Product for High throughput Glycan Screening

March 12, 2019 - ForteBio, the Biologics Business Unit of Molecular Devices, announced today the availability of a new assay kit for high throughput glycan screening at the BioProcess International (BPI) West 2019 conference. The Sialic Acid (GlyS) kit, which is designed for use on the industry leading Octet® instruments, presents a revolutionary opportunity to screen for optimal sialylation faster, earlier in development, and with more samples than allowed by conventional techniques.

Said Greg Milosevich, President of Molecular Devices, "The GlyS kit is part of the ForteBio promise for workflow and product innovations that help our customers make better informed decisions sooner, to reduce risk and time in development." The GlyS kit, available for use on all Octet systems is compatible with crude samples — no purification or digestion steps required. Relative sialylation results can then be combined in the software with titer data obtained on the Octet system to select clones that have high protein expression as well as optimal sialic acid content during early screening in cell line development.

Visit GlyS kit to learn more.

About Molecular Devices
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

ForteBio is a business unit of Molecular Devices, offering products that span multiple technology vectors including analytical instrumentation and software, clone picking and imaging, and automation and customization of engineering solutions. Our customers perform crucial work in life sciences research across academic, government and industrial settings, including pharmaceutical research, development and manufacturing.

Contact Information:
Craig Tin
Director, Regional Marketing
1 650 289 6862
Craig.Tin@moldev.com

Apr 26, 2018 : Molecular Devices and ForteBio combine to create new Biologics Solutions business unit to drive integrated workflow offerings for drug discovery and development

San Jose, CA, April 26, 2018 — Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the combination of its Biologics BioTherapeutics division with Pall Corporation’s ForteBio division—a world leader in label-free analysis for biomolecular detection and characterization that accelerates drug discovery and development.

The combined entity, called Biologics Solutions, will operate as a business unit within Molecular Devices and will involve the transition of all personnel and technology from Pall ForteBio to Molecular Devices, both operating companies of Danaher, a global science and technology innovator.

San Jose, CA, April 26, 2018 — Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the combination of its Biologics BioTherapeutics division with Pall Corporation’s ForteBio division—a world leader in label-free analysis for biomolecular detection and characterization that accelerates drug discovery and development.

The combined entity, called Biologics Solutions, will operate as a business unit within Molecular Devices and will involve the transition of all personnel and technology from Pall ForteBio to Molecular Devices, both operating companies of Danaher, a global science and technology innovator.

“We are bringing together the best in protein analysis and characterization, and the best in clone selection as a unified team to provide integrated workflow solutions for cell line development in biologics process development,” said Greg Milosevich, President of Molecular Devices. “By combining Pall’s ForteBio business with Molecular Devices Biologics BioTherapeutics division, we will offer streamlined and responsive support for improved customer confidence and save precious time in customer research, discovery and drug development.”

The increasing number of approved biologics and biosimilars in recent years has fueled the demand for technologies that enhance productivity in drug discovery and development. Currently, large numbers of hybridoma and cell clones have to be screened in early development stages for a number of product characteristics to select lead molecules and identify rare stable high producer clones. By integrating the teams that offer protein analysis technologies at ForteBio and clone picking technologies at Molecular Devices, the Biologics Solutions unit will improve the speed and efficiency in selecting lead molecules, generating highly productive cell lines and developing processes for manufacturing. The business unit will launch a newly combined ‘go-to-market’ team to expand its reach and service to its customers, improve customer intimacy, and offer truly integrated workflow solutions for therapeutic drug discovery and development.

Beginning in July 2018, the Biologics Solutions business unit will manage both the ForteBio and Biologics BioTherapeutics product portfolios under the newly created biologics brand within Molecular Devices.

About Molecular Devices
Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe.

For more information, please visit www.moleculardevices.com

Contact Information:
Craig Tin
Director of Marketing
1 650 289 6862
craig.tin@pall.com

Jan 03, 2018 : Obsolescence Notification for OCTET QK384 System

Pall ForteBio is announcing the end of sale of new and refurbished Octet QK384 systems worldwide on January 3, 2018. The Octet QK384 systems will reach their end of guaranteed support (EGS) on December 31, 2022. As you approach the end of the guaranteed support period, you have the choice of upgrading your system or continuing support on your Octet QK384 system.

Pall ForteBio is announcing the end of sale of new and refurbished Octet QK384 systems worldwide on January 3, 2018. The Octet QK384 systems will reach their end of guaranteed support (EGS) on December 31, 2022. As you approach the end of the guaranteed support period, you have the choice of upgrading your system or continuing support on your Octet QK384 system.

Pall ForteBio is committed to providing the highest level of customer care for all our products. Please see below for key timelines and support options that are now available for the Octet QK384 systems.

  • January 3, 2018: End of sale of new and refurbished Octet QK384 systems
  • December 31, 2021: Last day to purchase annual Service Contracts for Octet QK384 systems*
  • December 31, 2022: End of guaranteed support for Octet QK384 systems

*Last day to purchase annual Service Contracts for the specified system, covering up to the EGS date. After the EGS date, Pall ForteBio will continue to offer time and materials support on a best-effort basis.

Replace Your Instrument
Our Octet systems have evolved significantly in recent years and this presents an opportunity to step into a new dimension of performance.We have attractive trade-in offers in place to facilitate a smooth transition from the Octet QK384 system to an Octet RED384, HTX system or the newly launched Octet RED96e systems.

Keep Your Instrument
You can continue to purchase comprehensive and basic service contracts, performance maintenance and certification offerings for the Octet QK384 system that are valid up until the EGS date. After that date, on-demand services can be purchased on a time-and-materials basis but parts availability is not guaranteed.

We’re Here to Help
For more information, please contact your local sales or service representatives or fill out our technical support form.

Apr 05, 2017 : Pall Fortebio launches the Octet RED96e System for more versatile Biologics characterization

FREMONT, CA – April 5, 2017 – Pall ForteBio, the market leader in label-free biomolecular interaction analysis across academic research, drug discovery and development, process analytics, and manufacturing quality control today announced the launch of the new Octet® RED96e instrument. The new system introduces several key hardware and software features to extend the capabilities of the Octet platform.

"The Octet family of products has been an essential tool for customers developing novel therapeutics and biosimilars, providing more efficient and flexible assays for biomolecular characterization," said Dominik Arnold, General Manager of Pall ForteBio. "We listened to our customers and are excited to launch the new Octet RED96e instrument with enhanced unattended throughput, assay and sample versatility. Our goal is to deliver innovative products that continually offer higher data quality to improve the outcomes of life science research and development projects."

The Octet RED96e system detects a diverse range of biomolecules from small molecules to proteins to mammalian cells. The Bio-Layer Interferometry (BLI) technology used in the Octet platform offers a simple Dip and ReadTM microfluidics-free approach to biomolecular interaction analysis. The system enables direct detection of specific proteins and other biomolecules — even in complex mixtures and unpurified samples like cell culture supernatants and lysates. The 8‑channel Octet RED96e system performs quantitation of 96 samples in 32 minutes, and kinetic screening — on rates (ka), off rates (kd), and dissociation constants (KD) — of 64 samples in 1.5 hours. Assays can now be performed over a wider temperature range of 15-40°C on the Octet RED96e instrument, allowing thermodynamic and kinetics measurements of unstable proteins at lower temperatures, or biologically relevant molecules at physiological temperatures. A new evaporation cover for microplates also allows for greater walk-away run time, with minimal sample evaporation for up to 12 hours.  The new Octet Data Analysis HT software version released with the Octet RED96e system brings custom reporting options and multi-experiment analysis that reduces analysis time from hours to minutes for even faster decision-making.

About Pall ForteBio
Pall ForteBio is a division of Pall Life Sciences that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems facilitate real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. Pall ForteBio's analytical solutions enable more efficient and accurate characterization of drug candidates, delivering greater value to the drug discovery and development markets.

For more information, visit www.fortebio.com.
Or follow us on social media: LinkedIn | Twitter | Facebook | YouTube

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. Follow more information visit www.pall.com.

Corporate Media Contacts: Pall ForteBio | Craig Tin | Director Marketing | craig_tin@pall.com

Contact Information:
Craig Tin
Director of Marketing
1 650 289 6862
craig.tin@pall.com

Jan 09, 2017 : Pall ForteBio Acquires the Pioneer SPR Product Line from SensiQ Technologies to Expand Its Label-Free Interaction Analysis Portfolio

Freemont, CA, January 9, 2017 - Pall ForteBio, the developer and provider of industry-leading label-free biosensor technology platform, today announced that they will acquire the assets related to SensiQ's Pioneer product line and Pioneer products are immediately available for sales, service and support via Pall ForteBio.

"The Pioneer SPR systems are the perfect complement to the Pall ForteBio's Bio-Layer Interferometry family of label-free instruments," said Dominik Arnold, General Manager at Pall ForteBio. "It expands the range of solutions we offer our customers from small molecule fragment screening to detailed biologics characterization that are all critical in pharmaceutical drug discovery and development as well as academic research."

The Pioneer and Pioneer FE systems are sensitive, 3-channel, fully-automated surface plasmon resonance (SPR) instruments, with a unique OneStep® gradient injection technology. OneStep® uses a single injection to acquire kinetics for a full analyte titration up to 3 orders of Magnitude - offering unmatched speed compared to other SPR-based systems. Capable of analyzing up to 768 fragments in 24 hours, the Pioneer FE system is the ideal system for fragment screening in drug discovery. "Like the Octet systems, the Pioneer systems are enabling Technologies - providing more information faster than traditional methods and helping our customers in their quest to develop drugs in a more rapid and cost-effective manner," added Mr. Arnold.

Effective immediately, Pall ForteBio will assume responsibility for all sales, service, and support for the Pioneer FE and Pioneer instrument line and associated consumables. The closing of the asset acquisition is expected to take place in Q1 2017, after which time the product line will be integrated into its Fremont, California operations.

About Pall ForteBio
Pall ForteBio is a division of Pall Life Sciences that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems facilitate real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. Pall ForteBio's analytical solutions enable more efficient and accurate characterization of drug candidates, delivering greater value to the drug discovery and development markets. For more information, visit www.fortebio.com.

About Pall Corporation
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. Follow more information visit www.pall.com.

Or follow us on social media:

YouTube LinkedIn Twitter Facebook

Contact Information:
Mariann Kourafas
Director, Communications Pall Corporation
(508) 871-5469
sarah.vargas-hurlston@moldev.com

Contact Information 2:
Craig Tin
Marketing, Pall ForteBio

Aug 22, 2015 : ForteBio Adds Marketing and Sales Executive -- ForteBio Preparing for Product Sale

MENLO PARK, Calif. — August 22, 2005 — ForteBio, Inc., a life sciences company providing tools for the detection and analysis of biomolecules and their interactions, today announced the addition of Stephen Oldfield, Ph.D., to the new position of Vice President, Marketing and Sales. Dr. Oldfield joined the company in early August from Molecular Devices Corporation, where he was Vice President, Worldwide Marketing. He will report to Winnie H. Wan, Ph.D., President & Chief Executive Officer of ForteBio, and will be responsible for recruiting both marketing and sales personnel in preparation for the company’s first product launch later this year.

“I am delighted to have a marketing and sales executive with the highly relevant expertise that Stephen brings to ForteBio,” stated Dr. Wan. “We welcome his leadership as we develop our marketing strategy and put our sales force in place in anticipation of the launch of our first product later this year. Stephen has a broad and deep skill set — a combination of technical knowledge of the life sciences industry and a proven record in successful marketing and sales of consumable and reagent-driven systems, high level strategic planning, and developing and managing international marketing and sales distribution channels.”

Dr. Oldfield has been working in the commercial life sciences business for more than 20 years. Prior to his six years at Molecular Devices, he held senior marketing executive positions at Molecular Probes (now Invitrogen Detection Systems), FMC BioProducts (now part of Cambrex Corporation), Molecular Dynamics (now part of GE Medical Systems) and Pharmacia Biotechnology AB (now part of GE Healthcare). Dr. Oldfield received his Ph.D. in Pure & Applied Biology from the Imperial College, London and his B.Sc. in Genetics from the University of Sheffield in the United Kingdom.

About ForteBio, Inc. ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification and characterization of proteinprotein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities provide greater value in applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

Contact Information :
Winnie H. Wan, Ph.D.
Chief Executive Officer
650 322-1360 ext 111
wwan@fortebio.com

Aug 04, 2015 : Pall ForteBio Launches the Octet K2 System, Increasing Access to Sensitive Binding Interactions Analysis

PORT WASHINGTON, N.Y., August 4, 2015 — Pall ForteBio LLC, a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet K2 system, a new entry point into the Octet line of label-free interaction analysis systems. Now available globally, the Octet K2 system offers high-performance, budget-friendly kinetic characterization of antibody, protein and small-molecule binding interactions.

Using Pall ForteBio’s Bio-Layer Interferometry (BLI) technology, all Octet systems offer a fluidics-free alternative to surface plasmon resonance with a variety of off-the-shelf Dip and Read™ biosensors for more rapid assay development and optimization. The Octet K2 system increases accessibility to BLI as a two-channel instrument that provides exquisite binding affinity data, for molecules down to 150 daltons in size.

"Label-free users in academia and at startup biotech companies have historically been stuck between choosing to pay a premium for capacity they will never use or to settle for a lower-performance ‘starter’ system,” commented Robert Wicke, General Manager at Pall ForteBio. “The Octet K2 system offers scientists throughput to meet their budget without compromising assay sensitivity."

About Pall ForteBio

Pall ForteBio LLC is a division of Pall Life Sciences that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems facilitate real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. Pall ForteBio's analytical solutions enable more efficient and accurate characterization of drug candidates, delivering greater value to the drug discovery and development markets.For more information, visit www.fortebio.com.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter @PallCorporation or visit www.pall.com.

Contact Information :
Gemma Milan
Pall ForteBio
650-289-6800
Gemma_milan@pall.com

Sep 16, 2013 : ForteBio Launches Octet HTX System for Accelerated Drug Development

PORT WASHINGTON, N.Y., September 16, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of instrumentation for accelerated drug discovery and development, today announced the launch of the Octet® HTX system, the new flagship member of the Octet line of label-free interaction analysis systems. The Octet HTX system addresses the acute industry need for increased analysis speed and sample throughput when characterizing large numbers of therapeutic candidates.

Octet HTX

Octet systems provide unique insights into drug-target binding interactions, insights that are used to fine-tune the affinity and specificity of drug molecules. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously, a capability offered by no other stand-alone label-free platform. The system offers dramatic time savings for researchers studying large panels of drug candidates, and provides innovative data analysis tools for developers of monoclonal antibodies and other biotherapeutic entities. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as 2 minutes.

“The need for higher analytical throughput is a central theme with our pharmaceutical and biopharm customers,” noted Robert Wicke, General Manager at Pall’s ForteBio Division. “We believe researchers will be delighted by the Octet HTX system. The HTX system was engineered for speed while maintaining peak performance, and will directly address critical bottlenecks in the drug development process.”

The Octet HTX system was unveiled today at the BioProcess International 2013 conference in Boston, Mass.

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.

About Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences' technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.  

Contact Information :
Doug Novarro
Corporate Public Relations, Pall Corporation
516-801-9944
Doug_novarro@pall.com

Contact Information 2 :
Gemma Milan
ForteBio
650-289-6800
gemma_milan@pall.com

Feb 12, 2013 : ForteBio Launches New Dip and Read Anti-FLAG Biosensor to Facilitate Protein Research and Drug Development

PORT WASHINGTON, N.Y., February 12, 2013ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and ReadAnti-FLAG Biosensor for use on the company's Octet® and BLItz instrumentation systems. The new biosensor enables researchers to quickly and easily detect FLAG-tagged recombinant proteins for their quantitation and kinetic characterization, which are key steps in drug development.
"FLAG is a commonly used affinity peptide tag to enable protein detection and purification," said Christopher Silva, vice president of marketing for Pall's ForteBio division. "However, traditional methods for evaluating FLAG-tagged proteins rely on time-consuming, analytical methods, which can slow down drug discovery and development. Our new Anti-FLAG Biosensor, together with the BLItz instrument platform's ease of use or the Octet system's high throughput, is designed to greatly accelerate laboratory workflow, reduce time to results and increase cost-efficiency." 

The biosensor is pre-immobilized with Sigma-Aldrich's well-established, high-affinity ANTI-FLAG® M2 antibody, which has been cited in more than 30,000 journal articles over the last two decades. The high specificity of the antibody-based biosensor enables the direct quantitation of FLAG-tagged analytes in crude lysates, column eluents, cell lysates and cell culture supernatants.

Mr. Silva added that the new biosensor is intended to address strong demand for direct capture of FLAG-tagged proteins among ForteBio's Octet customers. It also should further broaden the appeal of the BLItz instrument platform — which enables label-free analysis of proteins using small sample volumes on a benchtop instrument — among academic researchers. "We are now pleased to offer our customers biosensors for the three most widely used peptide tags — HIS, GST and FLAG — among pharmaceutical and biotechnology scientists."

The Octet family of products is based on ForteBio's proprietary Bio-Layer Interferometry (BLI) technology. These instruments incorporate disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz instrument platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research.

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences' technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

 

Contact Information :
Doug Novarro
Corporate Public Relations, Pall Corporation
516-801-9944
Doug_novarro@pall.com

Contact Information 2:
Gemma Milan ForteBio
650-289-6800
Gemma_milan@pall.com

Jan 09, 2013 : ForteBio Launches Dip and Read Anti-Human Fab-CH1 Biosensor to Accelerate Human Biotherapeutic Drug Development

PORT WASHINGTON, N.Y., January 09, 2013 — ForteBio, a division of Pall Life Sciences and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read Anti-Human Fab-CH1 biosensor. The new biosensor enables an easy and rapid method for quantitation and kinetic characterization of human Fab, F(ab')2 and IgG - critical processes in drug discovery. Dip and Read biosensors are designed for use on ForteBio’s Octet® and BLItz™ instrumentation systems.

ForteBio Launches Dip and Read Anti-Human Fab-CH1 Biosensor

“The detection and characterization of human IgG is of paramount importance to research scientists,” said Christopher Silva, the ForteBio division's vice president of marketing. “However, traditional approaches to quantitation and kinetic characterization have been cumbersome, slow and expensive. Our new Anti-Human Fab-CH1 biosensor carries the popular CaptureSelect® IgG-CH1 ligand from BAC BV, a company that provides affinity tools widely used in purification of antibodies and antibody fragments. The new biosensor offers researchers unparalleled ease of use and time-to-result in a wide range of laboratory applications, enabling improved laboratory workflow and cost-efficiency.” The Anti-Human Fab-CH1 biosensor consists of a pre-immobilized high-affinity, anti-human CH1 affinity ligand that binds specifically to the CH1 domain of all four human IgG subclasses independent of the type of light chain. Its unique selectivity provides solid coverage of any human IgG derived Fab fragment without interference of notorious product-related contaminants like over-expressed free light chains. The high specificity of the biosensor enables direct analysis of human Fab/F(ab')2/IgG in crude lysates, column eluants, cell lysates and cell culture supernatants, providing a time-saving alternative to traditional analytical methods. The Octet family of products is based on ForteBio’s proprietary Bio-Layer Interferometry (BLI) technology. It incorporates disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research.

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Its membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall Life Sciences is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall Life Sciences’ technologies are also used in clinical institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

Contact Information :
Doug Novarro
Corporate Public Relations, Pall Corporation
516-801-9944
Doug_novarro@pall.com

Contact Information 2 :
Gemma Milan
ForteBio
650-289-6800
Gemma_milan@pall.com

May 31, 2012 : ForteBio Launches Dip and Read Ni-NTA Biosensor for Protein Analysis

PORT WASHINGTON, N.Y., May 31, 2012 — ForteBio®, a division of Pall Life Sciences (NYSE: PLL) and a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read™ Ni-NTA biosensor for use on its Octet® and BLItz™instrumentation platforms. The new biosensor is pre-immobilized with novel nickel-charged tri-nitrilotriacetic (Tri-NTA) groups enabling an easy, rapid and direct method for quantitation and kinetic analysis of polyhistidine-tagged (HIS-tagged) biomolecules. “Nickel provides an excellent binding medium for the stable capture of HIS-tagged proteins as part of quantitation and characterization studies,” said Christopher Silva, ForteBio division’s vice president of marketing. “However, standard formats for using this medium have been cumbersome, time-consuming and expensive. Now, our new Ni-NTA biosensor enables scientists to quickly and easily analyze HIS-fusion proteins with unsurpassed ease of use and workflow efficiency.” The Ni-NTA biosensor is designed for use in buffer and diluted complex media. Each biosensor can also be regenerated up to 10 times via a standard low-pH protocol in as little as two minutes for various applications such as acquisition of replicate data (same ligand/analyte pair) and “bucket-based” screening applications. ForteBio’s Octet family of products is based on the company’s proprietary BioLayer Interferometry (BLI) technology. It incorporates disposable optical Dip and Read biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists in biotherapeutic discovery, process development and academic research.

About ForteBio

ForteBio is a division of Pall Life Sciences, a unit of Pall Corporation. ForteBio provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. For more information, visit www.fortebio.com.

About Pall Life Sciences

Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. Pall technologies are also used to collect and process blood components and help protect patients from hospital-acquired infections. The company’s membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce.

About Pall Corporation

Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.7 billion for fiscal year 2011, is an S&P 500 company with almost 11,000 employees serving customers worldwide. Pall has been named a “top green company” by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.

Contact Information :
Gemma Milan
650-289-6800
gemma_milan@pall.com

Dec 19, 2011 : Pall Corp. Signs Agreement to Acquire Life Sciences Innovator ForteBio

PORT WASHINGTON, N.Y., December 19, 2011 — Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced it has entered into a definitive merger agreement to acquire ForteBio®, Inc., a leading provider of advanced analytical systems that accelerate the discovery and development of biotech drugs. The transaction is expected to close by February of 2012. Terms of the deal were not disclosed.

Headquartered in Menlo Park, Calif., ForteBio offers an array of innovative, label-free protein analysis instruments that will extend Pall's capabilities in the more than $1 billion biopharmaceuticals process monitoring market and in the protein research market. An ideal complement to Pall's existing microbiological monitoring platforms, ForteBio's portfolio of analytical solutions allows researchers to measure proteins in real time without the aid of fluorescent, radio or calorimetric labels or markers that can contaminate samples. This enables significantly easier, faster and better characterization of drug candidates, which can help improve process development and speed time to market.

"We are thrilled about the acquisition of ForteBio and the added value it enables Pall to bring to customers," said Larry Kingsley, Pall CEO and president. "BioPharmaceuticals continues to be the engine of our Life Sciences business and an important long-term growth accelerator. The addition of ForteBio's platforms into our business reinforces Pall's commitment to helping customers get their life-changing products to market safely and on time."

ForteBio's original Octet® family of products is based on the company's proprietary BioLayer Interferometry (BLI) technology. It incorporates disposable optical Dip and Read™ biosensors that measure multiple interactions in parallel, without the use of detection agents. For single-sample analysis, ForteBio recently launched its BLItz™ platform. The new platform revolutionizes the use of label-free protein analysis by making it more accessible and cost-effective for individual bench scientists and researchers.

"Pall's strong global sales channel will extend the reach of ForteBio instruments and better position us to capitalize on opportunities in emerging regions in Europe and Asia," said Joseph D. Keegan, Ph.D., ForteBio CEO and president. "Demand for label-free protein analysis continues to intensify and through the merger we now can bring the advantages of ForteBio systems to a wider range of customers."

Upon closing, ForteBio will become a wholly-owned subsidiary of Pall Corp. In the short term, the impact to Pall's results of operations will be immaterial. Completion of the merger is subject to certain customary closing conditions.

About Pall Corporation

Pall Corporation (NYSE: PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.7 billion for fiscal year 2011, is an S&P 500 company with almost 11,000 employees serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Forward-Looking Statements

The matters discussed in this report contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are those that address activities, events or developments that the Company or management intends, expects, projects, believes or anticipates will or may occur in the future. All statements regarding future performance, earnings projections, earnings guidance, management's expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Forward-looking statements are those that use terms such as "may," "will," "expect," "believe," "intend," "should," "could," "anticipate," "estimate," "forecast," "project," "plan," "predict," "potential," and similar expressions. Forward-looking statements contained in this and other written and oral reports are based on management's assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors.

The Company's forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance, and actual results, developments and business decisions may differ materially from those envisaged by the Company's forward-looking statements. Such risks and uncertainties include, but are not limited to, those discussed in Part I—Item 1A.—Risk Factors in the 2011 Form 10-K, and other reports the Company files with the Securities and Exchange Commission, including: the impact of legislative, regulatory and political developments globally; the impact of the uncertain global economic environment; the extent to which adverse economic conditions may affect our sales volume and results; changes in product mix, market mix and product pricing, particularly relating to the expansion of the systems business; our ability to develop and commercialize new technologies, enforce patents and protect proprietary products and manufacturing techniques; demand for our products and business relationships with key customers and suppliers, which may be impacted by their cash flow and payment practices; delays or cancellations in shipments; our ability to obtain regulatory approval or market acceptance of new technologies; our ability to successfully complete our business improvement initiatives, which include supply chain enhancements and integrating and upgrading our information systems; the effect of a serious disruption in our information systems; fluctuations in our effective tax rate; volatility in foreign currency exchange rates, interest rates and energy costs and other macroeconomic challenges currently affecting us; increase in costs of manufacturing and operating costs; our ability to achieve and sustain the savings anticipated from cost reduction and gross margin improvement initiatives; our ability to attract and retain management talent; the impact of pricing and other actions by competitors; the effect of litigation and regulatory inquiries associated with the restatement of our prior period financial statements; the effect of the restrictive covenants in our debt facilities; and our ability to successfully complete or integrate any acquisitions. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them, whether as a result of new information, future developments or otherwise.

Contacts:

Investor Relations

Patricia Iannucci
Pall Corporation
V.P. Investor Relations & Corporate Communications
pat_iannucci@pall.com
516-801-9848

Public Relations

Doug Novarro
Pall Corporation
Corporate Director Public Relations
doug_novarro@pall.com
516-801-9944

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com/a>

Follow us on Twitter @pallcorporation

Dec 05, 2011 : ForteBio Introduces BLItz, a Revolutionary, Micro-Volume Label-Free Analysis Platform for Personal Assays

San Diego, CA, December 5, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of BLItz™, a revolutionary new platform that will enable scientists — for the first time — to conduct label-free analyses of proteins using small sample volumes easily and cost-efficiently at their lab bench. The new platform was unveiled today at the IBC Antibody Engineering and Therapeutics Conference in San Diego, Calif. (Booth #206 at the Hilton San Diego Bayfront Hotel).

BLItz System - Drop and Read

“With BLItz, researchers will be able to perform specific protein quantitation, kinetics and affinity analyses of protein interactions with just a drop of sample in a simple ‘drop, read, done’ format at a price point below $20,000 per instrument,” said Christopher Silva, ForteBio’s vice president of marketing. “We believe BLItz will revolutionize the use of label-free protein analysis by making it more accessible than ever to individual bench scientists throughout the world. Ultimately, this will help to further drive basic research and biotherapeutic development.” Historically, label-free assays have been used selectively and relegated to institutions’ core labs due to their high complexity and expense. This has traditionally produced bottlenecks in biotherapeutic research and development as scientists may wait days and weeks to schedule their experiments and then hours or longer to obtain results. BLItz is small — taking up less surface area than a tablet personal computer — so it can fit easily in an individual scientist’s workspace and is simple to use. It requires only four microliters of sample — 15 to 20 times less volume than needed for traditional, SPR-based label-free assays or microplate-based ELISA assays. Additionally, its Dip and Read™ assays utilize disposable, ready-to-use biosensors to uniquely provide results in seconds to minutes. BLItz utilizes the same BioLayer Interferometry (BLI) technology that powers ForteBio’s flagship Octet® instrumentation platform, which enables real-time kinetics, affinity and quantitation measurements in high-throughput applications, with unprecedented ease of use and cost-efficiency. “ForteBio has a history of delivering disruptive technologies that have re-invented the label-free protein analysis space,” said Joseph D. Keegan, Ph.D., ForteBio’s chief executive officer. “In just seven years, many leading academic, government and corporate institutions have adopted our Octet platform and have consumed more than four million biosensors for use on the system. We look forward to making similar inroads with our new BLItz platform and anticipate that BLItz will help fuel further growth in proteomics.” The new BLItz system is designed for any researcher working with proteins, particularly those who analyze column fractions, monitor protein expression, perform reagent QC, identify mechanism of action and signaling and run protein engineering studies. More information about BLItz can be found at www.BlitzMeNow.com.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Nov 29, 2011 : ForteBio Launches Dip and Read Anti-GST Biosensor

MENLO PARK, CA, November 29, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the introduction of its Dip and Read™ Anti-GST biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables researchers to conduct quantitation and kinetic analyses with GST fusion proteins — widely used assays to detect protein interactions — with unprecedented ease of use, high-throughput and cost efficiency.

Dip and Read

“Our new, robust Anti-GST biosensor enables researchers to determine expression levels of GST-tagged proteins and cell lines in a matter of minutes, rather than hours that are typically required using standard ELISA methods, and then perform rigorous kinetic characterization of the selected clones immediately afterwards,” said Christopher Silva, ForteBio’s vice president of marketing. “This versatility is especially conducive to high-throughput analyses and enables users to greatly streamline their laboratory workflow to deliver results more quickly.” The Anti-GST biosensor enables easy and rapid quantitation of GST-tagged proteins in buffer, media or bacterial lysates, while facilitating kinetic characterization of macromolecular interactions between GST-tagged proteins and target analytes. Each biosensor can be regenerated up to 10 times during kinetic analysis with a standard low-pH protocol, for maximum cost-efficiency. The company also announced the launch of its Amine Reactive Second-Generation (AR2G) biosensor, also for use on the company’s Octet systems. This new biosensor enables kinetic characterization of macromolecular interactions between purified proteins and target analytes, with similar robustness and high-throughput as the company’s Streptavidin biosensor while allowing an alternative biosensor surface when desired for specific ligands. “Our AR2G biosensor enables researchers to conduct rapid immobilization of proteins and peptides for screening or kinetic experiments with greater ease of use, cost-efficiency and throughput than allowed by traditional methods,” said Mr. Silva. “Further, with its newly engineered biocompatible surface matrix, the AR2G biosensor provides enhancements over our first-generation AR biosensor, including greater signal intensity during the loading (immobilization of ligand) and association (detection of analyte) steps of an assay, increased loading density, decreased non-specific binding, and increased stability in a wide range of pH and salt conditions.” ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Jun 08, 2011 : ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies

MENLO PARK, CA, June 8, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Anti-Mouse IgG Fc Capture (AMC) biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables high-throughput rapid kinetic characterization and screening of mouse antibodies and other Fc-containing proteins with unprecedented ease of use and cost efficiency.

Dip And Read

“With the introduction of our new AMC biosensor, researchers can now benefit from ForteBio’s off-the-shelf, label-free biosensors during discovery projects using murine models, as well as when working with human antibodies,” said Christopher Silva, ForteBio’s vice president of marketing, noting that the company already offers its Anti-Human IgG Fc Capture (AHC) biosensor for analysis of human IgG antibodies. “Our AMC biosensor eliminates the need for inconvenient, labor-intensive steps typically associated with ELISA and SPR methods for screening and kinetic characterization, and thereby facilitates high-throughput research applications such as hybridoma screening and characterization.” The new AMC biosensor enables immobilization of mouse Fc-containing proteins upon the biosensor directly, from a crude or purified matrix, without the need to biotinylate. Additionally, AMC biosensors can be regenerated and reused up to 10 times. “Our new AMC biosensor can also work fluidly with ForteBio’s other research tools for increased speed, ease of use and cost efficiency,” said Mr. Silva. “For example, researchers using our Protein G biosensor to titer hybridoma samples can now use our AMC biosensor to perform kinetics and affinity analysis on resulting epitopes of interest — all from the same crude sample.” ForteBio’s Anti-Human IgG Fc Capture biosensor is ready to use on the company’s Octet instruments. ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Feb 15, 2011 : ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor

MENLO PARK, CA, February 15, 2011 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Octet RED96 System, as well as its new Dip and Read™ Protein L Biosensor for use on the company’s Octet platform. The product introductions further widen the scope and utility of the company’s flagship instrumentation system, which provides real-time, label-free analysis of biomolecular interactions, with unprecedented ease of use and cost-efficiency. The Octet RED96 system can rapidly measure protein and other biomolecule concentrations, as well as determine kinetics, affinity and specificity of protein-protein and protein-small molecule interactions. It extends the capabilities of the company’s premier Octet RED platform by featuring biosensor re-racking, which enables more efficient workflow, reduced amounts of capture molecule use and lower assay-running costs. “Our new Octet RED96 system enables life science researchers to perform analyses that have traditionally been conducted with SPR, HPLC, ELISA and other single-purpose microfluidics instruments, now with unmatched performance and cost-efficiency,” said Christopher Silva, ForteBio’s vice president of marketing. “For example, with concentration analysis, the system’s 8-channel simultaneous read-out quantitates 96 samples in 30 minutes and its re-racking feature extends the number of tests that can be performed with a single biosensor.” ForteBio’s new Dip and Read Protein L biosensor enables rapid and direct quantification of a broad set of kappa light chain containing immunoglobulins, including Fab fragments and single-chain variable fragments otherwise known as ScFv. “Protein L binds with high affinity to several more species and isotypes than both Protein A and Protein G, giving it broader potential applications,”said Mr. Silva. “With ForteBio’s new Protein L biosensor, which can be regenerated and reused, scientists can now obtain highly sensitive quantitation results in real time, in a cost-effective and easy-to-use manner. Further, our bioprocess customers will now be able to run a suite of assays in a multiplexed panel format using our Protein A, Protein G and Protein L biosensors.” ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Oct 21, 2010 : Hudson Robotics Chosen as Preferred Automation Vendor for ForteBio's Label-Free Work Cell

October 21, 2010, Springfield, NJ — Hudson Robotics, Inc., a leading provider of flexible solutions in laboratory automation, today announced they have been chosen as a preferred automation vendor for ForteBio's Label-Free Octet® platform work cell. This label-free work cell allows scientists to automate acquisition of protein-protein and protein-small molecule binding kinetic data, as well as direct quantitation assays - all of which can be carried out on the ForteBio line of instrumentation utilizing BioLayer Interferometry (BLI) technology. The work cell enables real-time, label-free analysis of biomolecular interactions and provides information on affinity, kinetics and concentration. ForteBio's Octet® platform provides instruments, Dip and Read™ biosensors, reagents and assay kits for analyzing biomolecular interactions in 96- and 384-well microplate formats.

Octet QK384 and RED384

Dip and Read biosensors are coated with a proprietary biocompatible matrix that is uniform and non-denaturing, with minimal non-specific binding. The tips are derivatized and ready for use in a diverse set of biomolecular applications spanning the entire small molecule and biotherapeutic drug discovery paradigm. Biosensors can also be customized for unique applications. Multiple layers can be bound and detected, opening a vast array of approaches to detecting and characterizing biological interactions. To date, over 2.5 million biosensors have been shipped, attesting to the high reproducibility, accuracy, precision and robustness of the platform. Chris Silva, Vice President of Marketing at ForteBio said, “ForteBio and Hudson have worked to develop an out-of-the-box, integrated automation solution that can be used with ForteBio’s Octet® QK384 and RED384 systems for small molecule analysis, fragment screening and protein characterization.” As described by Phil Farrelly, President of Hudson Robotics, “The label-free work cell enables researchers to fully automate a high-value protein binding assay in a very small, benchtop footprint. Hudson’s PlateCrane EX™ robot arm feeds both ForteBio’s biosensor racks and sample plates to the Octet reader.” He continued “Also part of this work cell is Hudson’s Micro10x robotic reagent dispenser, to prepare sample plates immediately prior to reading. A bar code scanner is included, to place the microplate’s barcode into the reader’s output data file. Finally, the included SoftLinx interface controls both instruments and instructs ForteBio’s software to load and run the appropriate protocol.” Mr. Silva continued, “ForteBio has elevated Hudson Robotics to ‘preferred’ automation vendorstatus due to their increased collaboration and implementation of current integrations in the field as well as the companies collaborative efforts to promote the integrated solution for target bioprocess, protein characterization and small molecule drug discovery applications. In addition the flexibility of Hudson's automated tools, their liquid handling and robotics allows Octet users to configure a work cell to meet their required workflows.” Data collected using the integrated work cell was presented at the Fragment Based Lead Discovery (FBLD) meeting by Roche in Philadelphia and Hudson plans to showcase this product at Lab Automation 2011 in Palm Springs, CA.

About Hudson Robotics, Inc.

Located in Springfield, New Jersey, Hudson Robotics, Inc. is a leader in automation solutions to accelerate life sciences research, offering a unique mix of instrumentation, customized software and scientific knowledge. The company provides automation solutions in drug discovery, high-throughput screening, proteomics and genomics and helps develop strategies that best meet customers’ unique needs, whether for an integrated system of automated laboratory equipment or for automating a single instrument. For more information, go to www.hudsonrobotics.com.

Contact Information :
Phil Farrelly
Hudson Robotics, Inc.
973.376.7400 ext. 202
pfarrelly@hudsoncontrol.com

Contact Information 2:
Lois Kaufman
Integrated Marketing Services
609.683.9055 ext. 203
lkaufman@imsworld.com

Contact Information 3:
Christopher M. Silva
ForteBio, Inc.
650.289.6814
csilva@fortebio.com

Sep 03, 2010 : ForteBio Announces Launch of Protein G Biosensor for Use on Company's Octet Instruments

MENLO PARK, CA, September 3, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG, an antibody molecule), from solution. Because it runs on the company’s label-free Octet instrumentation platform, the new biosensor enables such measurements with unprecedented speed, ease of use and cost-efficiency. The company also announced that it has completed International Standards Organization (ISO) certification of its biosensor manufacturing facility.

Biosensor closeup View

“Protein G uniquely binds to many mammalian IgGs, such as murine, goat, bovine and other IgGs, making it an important tool in antibody discovery, cell line development and production monitoring,” said Christopher Silva, ForteBio's vice president of marketing. “Traditional IgG quantification methods for numerous species and subtypes using Protein G, however, are complicated, labor-intensive and time-consuming. Now, with ForteBio’s new Protein G biosensor, researchers can obtain highly specific binding information in real time, in a cost-effective and easy-to-use manner.” Mr. Silva also noted that the company’s Protein G biosensor can be regenerated and reused, for increased workflow flexibility and cost-efficiency. The new biosensor comes with recombinant Protein G pre-immobilized on the surface and is ready to use on ForteBio’s Octet instruments. ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify kinetic characterization and quantitation by eliminating throughput and time-to-result limitations of traditional SPR-based assays and ELISA. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding. To date over 2.5 million biosensor assays have been run on Octet systems, a testament to the high reproducibility, accuracy and robustness of the platform. The company also announced that its biosensor manufacturing facility is now ISO 9001:2008-certified, underscoring the quality of its products.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Apr 20, 2010 : ForteBio Launches New-Generation Octet QKᵉ Instrument

MENLO PARK, CA, April 20, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QKe instrumentation system. The new system, the next generation of the company’s initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QKe system enables biosensors to be re-racked, for increased workflow flexibility and cost savings. “Since its introduction in 2005, our Octet QK product has gained popularity among life science researchers seeking a label-free system that offers increased ease-of-use, sensitivity, throughput and affordability for quantitation of proteins and kinetic characterization of biomolecular binding interactions,” said Christopher Silva, ForteBio’s vice president of marketing. “Our new Octet QKe system offers all of these benefits, plus greater sensitivity and a wider dynamic range, due to its two acquisition-rate settings and higher-performance spectrometer. The system's increased sensitivity is particularly important for researchers analyzing lower molecular weight proteins and peptides. And, because it also allows biosensors to be re-racked at the end of an experiment, the Octet QKesystem provides a significant value over other label-free systems.” The company also announced the introduction of its new Anti-Penta-HIS (HIS) biosensors for rapid, label-free quantitation of HIS-tagged proteins. The new Dip and Read™ biosensor comes with the highly specific Qiagen Penta-HIS antibody pre-immobilized on the surface and is ready to use on ForteBio’s Octet instruments for specific detection and quantitation of HIS-tagged proteins. “HIS-tagged proteins are commonly used in recombinant therapeutic protein development programs because they offer straightforward affinity purification and subsequent quantitation,” said Mr. Silva. “Our new ‘Dip and Read’ biosensor provides quantitation and subsequent affinity measurements in a single step, depending on the protein being investigated, without the need to purify from crude cell lysates. This process enables researchers to obtain quantitation, specificity and binding kinetics information on HIS-tagged therapeutic protein candidates with unprecedented ease of use, flexibility and cost-efficiency.” ForteBio’s Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
Marketing Communications Specialist
650-289-6800
gmilan@fortebio.com

Mar 09, 2010 : Tecan and ForteBio Automate Label-Free assays for Bioprocess and Drug Discovery Applications

March 9, 2010 — Tecan has become ForteBio’s preferred automation partner for real-time, label-free assays to support bioprocess and drug discovery workflows. The two companies have worked together to integrate the new ForteBio Octet® 384 platform, consisting of the Octet RED384 and the Octet QK384, on Tecan’s Freedom EVO® liquid handling workstation. The result is a robust, off-the-shelf integration that offers increased walkaway time and optional liquid handling for assay plate set-up.

Tecan 2

Tecan has designed a Freedom EVO deck extension plate to mount the Octet 384 instrument securely on the right hand side of the workstation. A robotic manipulator arm performs automated transport and handling of plates and sensor trays, and an 8-channel liquid handling arm with fixed or disposable tips is used to prepare assay plates. A MultiChannel Arm™ (MCA), with a 384- or 96-channel pipetting head, can also be specified for higher throughput applications. Kevin Moore, Tecan’s Director of Market and Application Management for BioPharma, said: “We are very pleased to be working with ForteBio to bring an automation solution to customers in this fast growing area of label-free detection.” ForteBio’s Octet platform enables reliable high throughput measurements for protein-protein, protein-peptide, protein-small molecule and fragment screening assays, using the innovative Dip and Read™ biosensors. The Octet systems use proprietary biolayer interferometry (BLI) to provide real-time, label-free analysis of biomolecular interactions. “We are delighted to partner with Tecan, enabling Octet customers to process batches of assay plates and automate sample handling for Dip and Read biosensor assays, allowing greater throughput and increased efficiency,” concluded Christopher Silva, ForteBio’s Vice President of Marketing.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2008, Tecan generated sales of CHF 396 million (USD 366.7 million; EUR 250.7 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/Swiss security number: 1210019).

About ForteBio

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
ForteBio
650 322 1360
gmilan@fortebio.com

Contact Information 2:
Paul Saville
kdm communications limited
+44 (0) 1234 210555
ideas@kdm-communications.com

Jan 11, 2010 : ForteBio Launches New Dip and Read Residual Protein A Detection Kit; Introduces Sidekick Offline Biosensor Immobilization Station for all Octet Instruments

MENLO PARK, CA, January 11, 2010 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company’s Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. The company also announced the introduction of its Sidekick Offline Biosensor Immobilization Station, which enables offline loading of reagents on biosensors, in tandem with any Octet instrument, for enhanced efficiency and assay performance. The Dip and Read Residual Protein A Detection Kit consists of biosensors and all the reagents required to quantitate Protein A or biosimilars such as MabSelect SuRe™, in the presence of human IgG. “Protein A detection is a critical quality control step during drug development and manufacturing, but traditional methods are labor-intensive, complicated and time-consuming,” said Christopher Silva, ForteBio’s vice president of marketing. “Our new Dip and Read Residual Protein A Detection Kit offers the same sensitivity levels as existing methods, but requires significantly less hands-on time and can be completed in half the time.” The new Sidekick Offline Biosensor Immobilization Station works alongside any Octet instrument and enables offline, simultaneous and uniform sample loading on all 96 biosensors on a biosensor tray. This increases efficiency by freeing up the Octet system for other uses. Additionally, the instrument shakes the samples, while keeping the biosensors immobile, which decreases the required incubation time by half, thereby doubling the biosensor preparation productivity. Further, for sandwich assays, this process significantly increases the assay’s sensitivity. “Our Sidekick instrument enables more samples to be run in significantly less time and with greater assay performance. It is ideal for rapid custom biosensor batch preparation and multistep Octet sandwich assays, which are used to detect impurities — such as residual Protein A in therapeutic antibody products,” said Mr. Silva. ForteBio’s Octet platform is based on the company’s proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650.289.6800
gmilan@fortebio.com

Sep 16, 2009 : ForteBio Launches Dip and Read Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies

MENLO PARK, CA, September 16, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched the new Dip and Read Immunogenicity Assay Kit for rapid detection of anti-drug antibodies (ADA) for use on the company's Octet® platform. The new assay kit provides life science researchers with new levels of throughput, speed and flexibility for measuring immune response to a therapeutic drug, an integral part of drug development. ”Traditional methods for anti-drug antibody detection can be time-consuming, insensitive and labor-intensive, and can result in low throughput,“ said Christopher Silva, ForteBio's vice president of marketing. ”ForteBio's new Dip and Read Immunogenicity Assay Kit overcomes these limitations, providing the needed sensitivity, increased drug tolerance and flexibility to detect both high- and low-affinity ADA. It accomplishes this by leveraging the Octet platform's real-time, label-free detection technology to essentially automate the relevant processing steps and eliminate any plate-washing components.“ The Dip and Read Immunogenicity Assay Kit's protocols work across many drug types, including antibodies, proteins and peptides. The assay kit provides biosensors and basic reagents to run two different assay configurations — an enzyme-linked bridging assay and a direct binding assay — for use with human, primate and other animal serum and plasma samples. ForteBio's Octet system is based on the company's proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of detection reagents. The platform includes the Octet QK384 system, which enables 384-well detection, 16-channel simultaneous readout with two plate positions, biosensor regeneration and re-racking, and automation capabilities for increased cost-efficiencies and throughput, as well as faster time to results. The Octet instrumentation software has optional FDA 21 CFR part 11 compliance tools required by GLP laboratories.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Jun 22, 2009 : ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet RED384 and The Octet QK384

MENLO PARK, CA, June 22, 2009 — ForteBio, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched two next-generation instruments: the Octet RED384 for protein, peptide, small molecule and fragment screening; and the Octet QK384 for protein and antibody assays. The new instruments will début this week at the 2009 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology conference in Seattle, Washington, and will provide life science researchers with unprecedented throughput, speed, flexibility and cost-efficiency when using the company’s Octet platform. The Octet RED384 and the Octet QK384 will enable 384-well detection, 16-channel simultaneous readout, biosensor regeneration and re-racking, and automation capabilities for biotherapeutic and pharmaceutical drug discovery assays. The new instruments will increase the cost-efficiencies of running ForteBio’s label-free Dip and Read™ biosensor assays in high-throughput mode, while enabling faster time-to-result for kinetic characterization and quantitation measurements. “The Octet RED384 and Octet QK384 will deliver revolutionary efficiency improvements for life science research applications that have traditionally been conducted using ELISA or SPR-based methods,” said Christopher Silva, ForteBio’s vice president of marketing. “For example, using our new instrumentation, IgG titer determination can be completed in less than 20 minutes, as opposed to four to five hours using traditional ELISA methods. This fast time-to-result is important for bioprocess and cell line development researchers because it will enable them to monitor their bioreactors and fermentation cultures in real time. Additionally, our new label-free instruments enable researchers to perform protein kinetic screening and characterization on a 384-well plate in about two hours. These analyses have traditionally been conducted using SPR systems, which provide lower throughput and are substantially more expensive than the new Octet 384 series instruments.” The new systems support two 384- or 96-well plate positions and enable a full complement of samples to be run in one plate, while the second plate holds buffers, diluents and controls. The system is also capable of regeneration and re-racking of biosensors. Online biosensor regeneration drives the cost per sample down while conserving valuable ligand. Re-racking of used biosensors allows for optional offline regeneration and flexible assay methods, freeing up valuable instrument time to run more assays. The Octet 384 series instruments enable competitively low running cost in the 10-20 cents range per data point for quantitation and kinetic characterization assays. The new systems are supported by Version 6 Octet software for data acquisition and analysis, which includes significant enhancements such as a 2:1 heterogeneous ligand binding model, data tracking and processing capabilities that assist in high-throughput screening. The new systems also include hardware and software robotic integration capabilities that support automation and database connectivity and can be licensed with optional 21 CFR Part 11 compliance tools. ForteBio's Octet biosensors are disposable and are configured in a standard microplate format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding. ForteBio also announced that the first batch of systems have been purchased by leading pharmaceutical and biotechnology companies after successful evaluations at customer sites.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

May 27, 2009 : ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on its Octet Platform

MENLO PARK, CA, May 27, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced that it has launched two new assay modules — for high-sensitivity protein quantitation and fragment screening, respectively — for use on the company's Octet® instrumentation platform. The new modules are available via software upgrades and will enable, for the first time, life science researchers who require these capabilities to access the high-throughput, ease-of-use and cost-effectiveness of ForteBio's leading label-free technology. The new high-sensitivity assay module can detect low nanogram per mL levels of analytes in quantitation mode. "For protein quantitation, life science researchers have traditionally run fluorescence and luminescence ELISA methods to achieve greater sensitivity in their assays. Now, using ForteBio's new modules, they can obtain highly precise results within an hour, enabling follow-up research to be conducted the same day," said Christopher Silva, ForteBio's vice president of marketing. "Additionally, labs that have transitioned from ELISA techniques to the Octet platform have improved their productivity by 50 to 70 percent, with no additional cost per well." ForteBio's off-the-shelf biosensors can be regenerated online, enabling the cost per well to begin at approximately 10 cents, while custom quantitation assays can be run by biotinylating the protein of interest using streptavidin biosensors. The new fragment screening assay methodology extends the company's small molecule analysis capabilities — available on ForteBio's Octet RED system — by enabling kinetic characterization and screening of fragment libraries that include compounds in the 150- to 300-dalton range. "Fragment-based lead generation is becoming an increasingly important component of drug discovery," said Mr. Silva. "Currently, fragment screening assays are typically run on lower-throughput, microfluidic-based SPR systems, which can become a bottleneck in the drug discovery process. The Octet platform's sensitivity and ability to assay precipitating compounds using a 'dip and read' format, its greater dynamic range and our new analysis software capabilities, enable rapid screening of fragment libraries in a microplate format." ForteBio's Octet biosensors are configured in a standard microplate format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Mar 03, 2009 : ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies

MENLO PARK, CA, March 3, 2009 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Anti-Human IgG Fc Capture (AHC) biosensor for use on the company’s Octet® instrumentation platform. The new biosensor enables more cost-effective, easy-to-use and rapid kinetic characterization and screening of human lgG antibodies and other Fc-containing proteins — important components in biomolecular therapeutic development — and further broadens the menu of Octet system applications.

“Researchers in bioprocessing and cell line development who study kinetic characterization of human IgG antibodies and other proteins can now benefit from the efficiencies of ForteBio’s Octet platform, which enables high-throughput, real-time, label-free detection and screening,” said Christopher Silva, ForteBio’s vice president of marketing. “The innovative, new AHC biosensor enables off-the-shelf, capture-based kinetics of human IgGs or other Fc-containing proteins without the need to biotinylate. It is also designed for use in buffer or crude supernatants, and can be regenerated and reused for increased cost-efficiency.” The new AHC biosensor leverages the Octet platform’s proprietary Bio-Layer Interferometry technology to enable kinetic profiling of human lgGs against analyte in a microplate well format. The biosensor surface can also be used to conduct ligand inhibition assays by expanding the variables that can be measured, such as blocking and unblocking analytes, affinity, and association and dissociation rates. The new AHC biosensor further expands the capabilities of the Octet platform which already supports quantitation of human IgG using Protein A. ForteBio’s Octet biosensors are configured in a standard 96-well format. Its biosensors simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. Octet biosensors are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate biotherapeutic drug development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio’s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Gemma Milan
650-289-6800
gmilan@fortebio.com

Sep 23, 2008 : ForteBio, Inc. Closes $25 Million in Series C Financing

MENLO PARK, CA, September 23, 2008 — ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of life science and pharmaceutic products, today announced the closing of $25 million in Series C financing, led by OrbiMed Advisors, a top global healthcare investment firm. MPM Capital also participated as a new investor in this financing round, as did existing investors Alloy Ventures, Versant Ventures, The Vertical Group and Latterell Venture Partners.

“With this new financing, ForteBio is well-positioned to continue to introduce industry-leading products, expand our market globally and achieve profitability,” said Joseph D. Keegan, Ph.D., president and chief executive officer of ForteBio. “We are also delighted to add such renowned life science investors as OrbiMed Advisors and MPM Capital to our team and strongly value the continued support of our existing, highly-respected investors.”

Since launching its Octet® QK System in late 2005, ForteBio has grown rapidly. It now has 11 biosensors (consumables) on the market and counts all of the leading biotechnology companies and 18 of the top 20 pharmaceutical companies as customers, many of which have purchased multiple systems. This year ForteBio introduced its Octet RED system and additional biosensors, expanding its quantitation applications and broadening its small molecule kinetics capabilities. The company also added a European direct selling team and numerous distributors throughout the world this year in order to better serve its growing global pharmaceutical, biotechnology, academic and government customer base.

“We are pleased to become involved with a company of ForteBio’s caliber, which has already demonstrated strong market success and has quickly become a leader in advancing life science development and bioprocessing,” said Jonathan Wang, Ph.D., managing director, Asia, for OrbiMed Advisors. “We are eager to support Dr. Keegan and his strong management team as they drive the company to achieve its potential.” Dr. Wang, along with Kazumi Shiosaki, Ph.D., of MPM Capital, will join the ForteBio board of directors.

ForteBio also announced today that Dr. Keegan will present an update on company activities at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 2:30 p.m. EDT. His presentation will take place in Ballroom A at the Grand Hyatt Hotel in New York City. A live audio webcast of the presentation will be available at http://events.streamx.us/US/event/eventdetails.aspx?id=ubs20080922 and will be accessible until October 25, 2008.

About OrbiMed Advisors, LLC

OrbiMed is the world’s largest life sciences and healthcare-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in close to 100 companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages. OrbiMed has established the first pan-Asia life sciences-dedicated venture capital fund and has opened offices in Shanghai and Mumbai. For more information, visit www.OrbiMed.com.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate life science development. These systems enable real-time analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio‘s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.

Contact Information :
Joseph D. Keegan, Ph.D.
President and CEO
650-322-1360
jkeegan@fortebio.com

Apr 03, 2008 : ForteBio Announces New Octet RED System for Drug Candidate Characterization and Selection

MENLO PARK, CA, April 3, 2008 — ForteBio®, Inc., a life science company that develops and sells analytical tools to accelerate the development of therapeutic products, today announced the launch of the Octet® RED System, for label-free, real-time kinetic analysis of drug compounds. The new system brings unparalleled ease-of-use, sensitivity, throughput and affordability to the analysis of small molecules, peptides and proteins for research, development and bioprocessing. The Octet RED System will debut at the Society for Biomolecular Sciences’s 14th Annual Conference and Exhibition to be held April 6-10, 2008, in St. Louis, Missouri (Booth #1112).

“In drug discovery and development, kinetic analysis of drug compounds has been limited to highly trained specialists using expensive, complex and time-consuming instrumentation,” said Joseph D. Keegan, Ph.D., president and chief executive officer of ForteBio. “The Octet RED System provides higher sensitivity to enable label-free detection and analysis of low molecular weight molecules that can be performed easily, quickly and inexpensively and with higher throughput, as a routine laboratory procedure by any user, including non-experts.”

The degree to which a drug compound binds to a therapeutic target helps predict a drug candidate’s potency and effectiveness, and is a significant component of drug discovery and lead optimization. A label-free method of analysis is increasingly preferred because it avoids label interference with the binding activities of the therapeutic target. The Octet RED System is based on ForteBio’s proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of chemical labeling. The Octet RED System’s high sensitivity and rapid data acquisition capabilities enable analysis of low molecular weight molecules that interact extremely quickly, which is critical for comprehensive kinetic characterization of drug candidates.

“Label-free interaction analysis is a growing area for advancing leads in drug discovery and research,” said Dr. Keegan. “Now, by enabling pharmaceutical and biotechnology companies to conduct this analysis earlier in the process, in a faster and more affordable manner, the Octet RED System will help these companies accelerate drug development by validating screening campaign hits.”

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. Most importantly, ForteBio‘s analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Joy Concepcion
Product Manager
650-289-6819
jconcepcion@fortebio.com

Sep 18, 2007 : ForteBio Announces Executive Change

MENLO PARK, Calif. — September 18, 2007 — ForteBio, Inc., a rapidly growing life science company that develops and commercializes analytical instruments and consumables to accelerate and improve therapeutics development, announced today that Joseph D. Keegan, Ph. D., has been named president and chief executive officer, beginning September 24, 2007. ForteBio founding CEO Winnie H. Wan, Ph.D., who is credited with building the company into an emerging leader in the label-free technology market, will continue to serve on the board of directors. Dr. Keegan was most recently president and chief executive officer of Molecular Devices Corp. (MDC) before it was acquired by MDS, Inc. earlier this year.

“ForteBio is experiencing significant growth as our enabling technology breaks down ease-of-use and cost barriers to make widespread application of real-time label-free kinetics and quantitative analysis a reality,” said Dr. Wan. “I am pleased that we have someone of Dr. Keegan's caliber, with a proven record in building and managing later-stage life science businesses, to lead the company to the next stage.”

Dr. Keegan has more than 25 years of experience managing life science tools businesses. During his 9-year tenure at MDC, Dr. Keegan grew the company's revenues from $30 million to $190 million through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS for $615 million. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as president of Worldwide Tissue Culture and vice president, general manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was vice president of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the board of directors of Alpha Innotech Corporation, BioImagene, Inc. and Seahorse Bioscience Inc. Dr. Keegan holds a Ph.D. in physical chemistry from Stanford University.

“ForteBio launched its first product — the Octet System — in late 2005 and its placement at the majority of the top 20 pharmaceutical companies, as well as numerous biotechnology companies, is a testament to its value as a tool for therapeutic development,” said Craig C. Taylor, board director for ForteBio and partner at Alloy Ventures, the lead investor in the company. “Under Dr. Wan's leadership, the employees of ForteBio have developed a series of productive, quality instruments and reagents based on a technology that I think has considerable further potential. Given Dr. Keegan's experience, we are all excited that he is joining us to help the company realize that potential.” Mr. Taylor noted that to date the company has successfully launched multiple new products, and its instrument platforms and biosensors are now sold in 32 countries. The company has also established manufacturing capabilities in both Menlo Park and Shanghai, China.

“I am eager to lead ForteBio, as I believe that the company has tremendous opportunities for growth in the rapidly expanding label-free technology market,” said Dr. Keegan. “I look forward to building upon the company's success to date.”

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Joy Concepcion
650-289-6819
jconcepcion@fortebio.com

Aug 20, 2007 : ForteBio Expands International Distribution Network

MENLO PARK, Calif. — August 20, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, announced today that it has signed two new distributors to sell and distribute its Octet System of instruments and related consumables. The company named Bucher Biotec AG, Switzerland, as its exclusive Swiss distributor and Millennium Science Pty Ltd, Australia, as its distribution partner in Australia and New Zealand. The announcement underscores the growing global demand for ForteBio's life science analytical tools among pharmaceutical and biotechnology researchers.

“The expansion of our distribution network for the Octet System in both Europe and Australia will accelerate our efforts to further penetrate and serve these key markets,” said Winnie Wan, Ph.D., President and Chief Executive Officer. “We chose these two distributors because of their expertise and focus on drug-discovery technologies. Our objective is to meet the growing demand for label-free solutions that are flexible, cost-efficient and accurate.”

First launched in 2005, ForteBio's Octet System is now offered in 32 countries, providing scientists with real-time information in therapeutic and bioprocessing development applications. The company's analytical tools are designed to help accelerate the selection and characterization of therapeutic candidates by generating real-time kinetic and quantitative results quickly and easily.

Bucher Biotec AG (www.bucher.ch) is a privately held Swiss distributor that has represented major US, European and Japanese manufacturers of scientific instruments and associated consumables for life sciences research for nearly 30 years. Millennium Science Pty Ltd (www.mscience.com.au) is a specialist distribution company established in 1999 specifically to source, supply and support high technology solutions to the Australasian Life Science market. Millennium Science partners with carefully selected manufacturers who are, typically, market leaders in their chosen fields and are equally customer focused.

About ForteBio, Inc. 

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Winnie Wan, Ph.D.
President and Chief Executive Officer
650-322-1360
wwan@fortebio.com

Contact Information 2:
Roland Bucher
Chief Executive Officer
+41 (0)61 269 1111
fortebio@bucher.ch

Contact Information 3:
Bren Collinson.
Managing Director
+ 61 3 9830 7922
sales@mscience.com.au

Aug 13, 2007 : ForteBio Strengthens Portfolio with New Biosensors for Research and Development

MENLO PARK, Calif. — August 13, 2007 — ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, today announced two new product extensions to its Octet™ System. The Anti-Murine IgG Biosensor — Quantitation grade, and the Streptavidin High Binding FA Biosensor — Screening grade, extend the Octet System's concentration determination and kinetic analysis capabilities, respectively, broadening the product offering into additional research-focused applications.

“We are continually expanding our menu of surface chemistries to serve the growing demand for label-free detection in new areas of therapeutic research and development,” said Winnie Wan, President and Chief Executive Officer. “Since the launch of the Octet System less than two years ago, we have responded quickly to the needs of the research market by developing seven compatible biosensors that expand the system's applications in therapeutic development and bioprocessing.

The Anti-Murine IgG Biosensor — Quantitation grade, provides accurate concentration determination of mouse and rat sera or supernatants. With the Octet System, fast and accurate results for 96 samples can be achieved in 30 minutes. The Streptavidin High Binding FA Biosensor — Screening grade, provides triple the binding capacity for increased signal-to-noise ratios. These biosensors enable better kinetic screening and analysis of smaller proteins and fragment antibodies (Fabs). With increased ratios, custom quantitation assays for most proteins can also be developed.

The Octet System is a label-free, fluidics-free, real-time system for biomolecular interaction analysis of protein kinetics and Quantitation. It is currently used by pharmaceutical and biotechnology companies in applications ranging from target identification and validation to bioprocess development.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information 2:
Winnie Wan, Ph.D.
President and Chief Executive Officer
650-322-1360
wwan@fortebio.com

Jul 10, 2007 : Katherine Flagg Joins ForteBio as Vice President of Sales

MENLO PARK, Calif. — July 10, 2007— ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, announced today the appointment of Katherine J. Flagg as Vice President of Sales, reporting to Winnie H. Wan, Ph.D., President and Chief Executive Officer. In this new position at ForteBio, Ms. Flagg will lead the company's North American sales and field application scientist teams. She is also responsible for ForteBio product distribution in Europe, Asia and other parts of the world. Ms. Flagg joined ForteBio from Rapid Micro Biosystems, where she was Vice President, Business Development.

“We are so pleased to have someone with Katherine's expertise joining ForteBio at this time,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer. “Her familiarity with the international biotechnology and pharmaceutical industry is particularly helpful given ForteBio's goal of penetrating the life science markets in both the U.S. and Europe with our Octet System for label-free, real-time analysis of molecular interactions.” Ms. Flagg has nearly 20 years experience in the life sciences industry, including 9 years at BioVeris/IGEN Corporation (recently acquired by Roche), where she held a number of positions with increasing sales and management responsibilities. As Director of Sales of Life Sciences and BioSecurity, she successfully led a global account strategy to increase sales to major pharmaceutical companies in both Europe and the U.S. Previously, at Pharmacia Biotech (now GE HealthSciences), Ms. Flagg represented the company's automated DNA sequencing and synthesis products.

Ms. Flagg received her BS in Nutrition from Douglass College at Rutgers University. She is a member of the Laboratory Robotics Interest Group and the Parenteral Drug Association.

About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Winnie H. Wan, Ph.D.
President & Chief Executive
650-322-1360 ext 6888
wwan@fortebio.com

Jun 29, 2007 : New Biosensors expand applications for research and assay development

In ForteBios' continuing effort to expand the applications on the Octet System, we are launching two new biosensors for the kinetic analysis and concentration determination for research, development and production of antibody and protein therapeutics.

The following Screening and Quantitation grade biosensors are now available for use on the Octet System.

Anti-Murine IgG Biosensors - Quantitation Grade

• Determine mouse or rat IgG concentration based on a standard calibration

• Dynamic range: 1-100 ug/mL
• Precision < 10% CV
• Compatible with sera, cell culture supernatants and hybridoma supernatants

Streptavidin High Binding FA Biosensors - Screening Grade

• Higher streptavidin density for increased immobilization capacity
• Screening grade biosensors have baselines that are stable for < 15 minutes
• Ideal for screening of proteins requiring higher signal to noise
• Ideal for custom quantitation assays using biotinylated proteins

The Octet System is a label-free, fluidics-free, real-time system for biomolecular interaction analysis of protein kinetics and quantitation. It is currently being used by both pharmaceutical and biotechnology companies in applications ranging from target ID and validation to bioprocess development .

Contact us for more information and pricing.

Contact Information :
Joy Concepcion
Product Manager
650-289-6819
jconcepcion@fortebio.com

Contact Information 2:
Matthew Kirtley
Product Manager
650-289-6827
mkirtley@fortebio.com

Jan 04, 2007 : ForteBio Announces the Appointment of Bill Albright as Chief Financial Officer

MENLO PARK, Calif. – January 4, 2007 – ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, announced today the appointment of William A. Albright, Jr. as the company’s Chief Financial Officer. Mr. Albright has more than 20 years of medical device and biotechnology experience in both finance and executive management, most recently as Chief Financial Officer and Senior Vice President, Finance and Operations of Xenogen Corporation, which was acquired by Caliper Life Sciences in 2006.

“It is with great pleasure that we welcome Bill to ForteBio," stated Winnie H. Wan, Ph.D., President and Chief Executive Officer. “His extensive experience and proven track record, both in commercial operations and equity financings, will be great assets to ForteBio as we continue to penetrate the biotechnology and pharmaceutical laboratory markets with our Octet System for label-free, real-time analysis of molecular interactions.”

At Xenogen, a leading provider of novel in-vivo imaging (bioluminescence) systems, Mr. Albright raised more than $60M in financings within 13 months, including a $30M initial public offering. After helping to expand the sales force and manufacturing operations, and significantly increasing the company’s valuation, he led the merger with Caliper Life Sciences, which was completed in August 2006. Mr. Albright’s expertise in general management and organization of growth and turn-around companies includes executive positions at FlowMedica, Inc., as Chief Executive Officer; Nexell Therapeutics, Inc., as President and Chief Executive Officer; and as Chief Financial Officer at LocalMed, Inc., Connetics Corporation and ChemTrak, Inc.

At ForteBio, Mr. Albright will be responsible for the company’s finance organization, managing the company’s operations functions, raising additional capital and working with the CEO on major business transactions. He received an MBA from Harvard Business School and holds both his BS and MS degrees in Biological Sciences from Stanford University.

About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Winnie H. Wan, Ph.D.
President & Chief Executive
650-322-1360 ext 112
wwan@fortebio.com

Dec 07, 2006 : ForteBio Launches New Biosensors to Increase the Flexibility of the Octet System

MENLO PARK, Calif. — December 7, 2006 — ForteBio, Inc. announced today the launch of the Amine Reactive and Protein A Biosensors for use on ForteBio's Octet System, a label-free, real-time detection system for the analysis of molecular interactions. The new biosensors expand the menu of Octet applications, providing convenient kinetic analysis and concentration determination for the development of antibody and protein therapeutics.

The ForteBio Octet System is currently used by both pharmaceutical and biotechnology companies in applications ranging from target validation to process monitoring. With the new Amine Reactive Biosensors, customers can analyze a wider range of kinetic interactions by directly coupling the target molecule of their choice using familiar techniques.

“The Amine Reactive Biosensors create a more open platform that enables a wider variety of proteins to be directly coupled to the biosensors for the Octet System,” said Winnie Wan, CEO of ForteBio, Inc. “This enhancement provides users the flexibility and throughput in kinetic analyses that can support all phases of bioprocessing for selection, screening and validation of therapeutics undergoing development and production.”

The Amine Reactive Biosensors can be derivatized individually or in batch mode using a standard coupling chemistry, which maximizes both flexibility and throughput on the Octet System. Customers are already using the Octet System with Amine Reactive Biosensors to accelerate their clonal selection and screening protein affinities. Kinetic analysis on the Octet System is simple, convenient and easily scaled to match workflow.

ForteBio has also further expanded its Octet System menu with the launch of the Protein A Biosensors for measuring antibody concentrations in the development and production of therapeutics. By expanding the dynamic range for quantitation, Protein A Biosensors have broad applications for both upstream and downstream bioprocessing. They are easy to use with minimal sample preparation and up to 96 determinations in about 30 minutes. With rapid and accurate turnaround of results, Protein A Biosensors are used in process development laboratories to monitor bioreactor production and to optimize downstream processing such as purification.

A customer presentation and exhibit of ForteBio's Octet System will be at the IBC Antibody Engineering Conference in San Diego, December 10 through 14, Booth 301.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Winnie Wan
CEO
650-322-1360
wwan@fortebio.com

Jul 18, 2006 : ForteBio Adds Bernelle Saperstein to its Management Team

MENLO PARK, Calif. — July 18, 2006 — ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, said today that Bernelle H. Saperstein has joined the company as Vice President, Manufacturing Operations, a new position. Ms. Saperstein comes to ForteBio from BD-Immunocytometry Systems, where she led a large team responsible for manufacturing and testing reagents for cell analysis.

“Bernelle is an extremely knowledgeable operations executive with manufacturing and materials experience in analytical and diagnostic systems and chemical and pharmaceutical production,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “We wanted an experienced executive to oversee increasing manufacturing capacity at both our Menlo Park facility and our wholly owned subsidiary in Shanghai, China, in order to meet our expanding shipment requirements. I am delighted to have Bernelle's expertise on our management team.”

Ms. Saperstein's broad-based expertise encompasses all aspects of operations, including planning, inventory and expense control, productivity improvement, quality system implementation and maintenance, regulatory compliance, site management and HR/labor relations. She joined ForteBio in July 2006 from BD-Immunocytometry Systems, where she was Director, Reagent Operations. Previously, she was Vice President, Operations at First Medical, a subsidiary of Sigma Diagnostics. Earlier, she spent more than a decade at Roche Diagnostics where she held a number of management positions with increasing responsibilities, lastly as General Manager. Ms. Saperstein began her career at Merck, where for nearly 20 years she worked first at Merck Research Laboratories and later at the company's Calgon Corporation subsidiary. She received her BS in chemical engineering from Virginia Tech.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit www.fortebio.com.

Contact Information :
Winnie Wan
President & Chief Executive
(650) 322-1360 ext. 111
wwan@fortebio.com

Jun 15, 2006 : ForteBio Appoints Plexxikon CEO Peter Hirth to its Board

MENLO PARK, Calif. – June 15, 2006 – ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, today announced the election of K. Peter Hirth, Ph.D., to its Board of Directors. Dr. Hirth is Co-Founder and Chief Executive Officer of Plexxikon, a biotechnology leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease.

“I am very pleased to welcome Peter Hirth to our board, as he brings extensive experience in drug development in the markets we serve, namely the biotechnology and pharmaceutical industries,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “Peter’s participation as a board member will help ForteBio to identify new trends in drug development and better define our customers’ needs, particularly in the small molecule drug market.”

Dr. Hirth co-founded Plexxikon in December 2000, and has 20 years of biotechnology and pharmaceutical discovery and development experience. Previously, he was president of Sugen, Inc. until the sale of the company to Pharmacia Corporation in 1999. At Sugen, he helped build the company from its inception and advanced several kinase inhibitors through clinical trials for the treatment of oncology. Prior to Sugen, Dr. Hirth was a vice president in research with Boehringer Mannheim where, among other responsibilities, he successfully led the company's erythropoietin program. Previously, he also was a research scientist with the Max Planck Institute, following the completion of his post doctoral work at the University of California, San Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg University, Germany.

In addition to Dr. Hirth, other members of the ForteBio board include Dr. Wan; Brian Atwood, Co-Founder of Versant Ventures; Yue-Teh Jang, Ph.D., General Partner of the Vertical Group; Deborah Neff, President and Chief Executive Officer of Predicant Bioscience, Inc.; Craig Taylor, Partner at Alloy Ventures; and James Woody, M.D., Ph.D., General Partner at Latterell Venture Partners.

About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

Contact Information :
Winnie H. Wan, Ph.D.
President & Chief Executive Officer
650-322-1360 ext. 111
wwan@fortebio.com

May 31, 2006 : ForteBio Opens European Sales and Support Office

Menlo Park, CA, May 31, 2006 -ForteBio, Inc., developer of label-free systems for real-time detection and analysis of molecular interactions, today announced the opening of their European Sales and Support Offices in The Netherlands.

The next generation of analytical tools for life science research, ForteBio’s Octet™ System accelerates the selection and characterization of antibody candidates by generating real-time quantitative and kinetic results quickly and easily – even in crude samples. Local applications support will enable ForteBio’s European customers to rapidly optimize their assays and take advantage of the new biosensor products being introduced over the coming months.

“We are experiencing increasing demand for the Octet System in Europe,” said Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “The new sales office gives us an opportunity to provide higher levels of service and support to help our customers achieve the benefits of real-time analysis for therapeutic antibody and protein characterization. The team in Europe will take ForteBio to the next level of development in this important market.”

Fortebio’s European Sales and Support Office will be locally managed by TouchDown Biomarketing B.V. Mr. Tony Bartlett, Director of Business Development for ForteBio in Europe, stated, “Our team of application scientists, engineers and account managers has experience from some of the leading research laboratories in Europe. We will provide ForteBio with the direct market presence essential for growth and business development. ForteBio’s customers will benefit from timely scientific and technical information as well as access to hands-on expertise.”

About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of biotherapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio’s analytical capabilities provide greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

About TouchDown Biomarketing B.V.
TouchDown Biomarketing B.V. offers operational management and support to technology companies for the successful commercial introduction of innovative products into the European life sciences marketplace. With extensive business networks in Europe, USA and Japan, TouchDown Biomarketing has established a number of partnerships to provide the most optimal portfolio of services. The company is located in Bemmel, The Netherlands. For more information, visit www.touchdown-biomarketing.com.

Contact Information :
Stephen Oldfield, PhD
Vice President, Marketing and Sales
650 322-1360 ext 135
soldfield@fortebio.com

Contact Information 2:
Tony Bartlett
Director of Business Development
+31 (0)481-420099
tbartlett@fortebio.com

Nov 29, 2005 : ForteBio Introduces the Octet System for Antibody and Protein Therapeutics Development

MENLO PARK, Calif. — November 29, 2005— ForteBio, Inc. today announced the commercial introduction of the company's first product, the Octet™ System for label-free, real-time detection and analysis of molecular interactions. The next generation of analytical tools for life science research, Octet accelerates antibody development by generating real-time quantitative and kinetics results quickly and easily. Ready to use, consumable biosensors provide a cost-effective way to make critical measurements even in crude samples and at early stages in antibody development. New applications are easily addressed by offering new biosensors with modified surface chemistries.

The ForteBio Octet System is based on a proprietary technique called BioLayer Interferometry (BLI). The Octet System incorporates a sensitive optical detector and a unique series of application-specific biosensor consumables. The system was validated in beta testing conducted at Genzyme Corporation, KaloBios Pharmaceuticals, Inc., Raven biotechnologies, inc. and a number of other leading biotechnology and pharmaceutical companies. Researchers achieved success in the real-time analysis of therapeutic antibodies and proteins; and Octet provides unique capabilities that will allow expansion into a number of different life-science applications. Future generations of BLI technology will be optimized for small molecule detection and clinical immunogenicity.

Raven has replaced ELISA methods with ForteBio's Octet System as the primary assay during cell culture and process development. “Octet gives us product titres quickly and accurately from crude cell culture samples,” commented Dr. Hugh Graham, head of upstream manufacturing at Raven. “This helps us acquire more data in real time and thus improve our processes rapidly.”

“By collaborating with scientists/researchers at our biotech and pharma beta sties, we were able to optimize our technology to meet their specific needs,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “We are very pleased with the acceptance of our proprietary technology and expect that the Octet System will be a valuable tool in the selection and characterization of therapeutic antibodies in development.”

ForteBio will be presenting two technical posters, and the Octet System will be available for demonstration, at the IBC Antibody Therapeutics meeting in San Diego December 6 through December 8.

To inquire about purchasing an Octet System, please contact Stephen Oldfield at 650 322-1360 ext 135 or via email at soldfield@fortebio.com.

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification and characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities provide greater value in applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

Octet is a trademark of ForteBio, Inc.

Winnie H. Wan, Ph.D.
President & CEO
ForteBio
650 322-1360 ext 111
wwan@fortebio.com

Oct 26, 2005 : ForteBio Raises 17.3 Million in Series B Financing - Funding Will Support Launch

MENLO PARK, Calif. — October 26, 2005 — ForteBio, Inc., a life sciences company providing tools for the detection and analysis of biomolecules and their interactions, today announced the close of a $17.3 million Series B Preferred Stock financing. The round was led by The Vertical Group, a New Jersey-based venture capital firm that is focused on the fields of medical technology and biotechnology. All of the company's existing investors, Agilent Ventures, Alloy Ventures, Latterell Venture Partners, and Versant Ventures, participated in this financing.

“We are enthusiastic about the prospects for ForteBio's impressive platform technology and instruments, and their opportunity to achieve near-term revenues,” commented Yue-Teh Jang, Ph.D., General Partner of The Vertical Group. “Furthermore, the company's first product, Octet™, has unique capabilities that will allow expansion into a number of different life-science applications.” Dr. Jang, along with Brian Atwood of Versant Ventures, will join the ForteBio Board of Directors. “I am very pleased by the addition of The Vertical Group to our existing group of top-tier investors, who continue to strongly support ForteBio,” stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. “The capital raised to date provides the funding required to assemble our marketing and sales organization in preparation for the launch of our first product. In addition, we will continue our investments in further applications for our current instrument platform and in the development of our next generation of instrument products.”

ForteBio is preparing for a fourth quarter 2005 launch of its first product platform, Octet. An integrated system for the quantitation and kinetic analysis of biomolecules, Octet will be initially positioned to accelerate the selection and characterization of therapeutic antibodies and proteins.

About ForteBio's Investors

Additional information about each of ForteBio's investors may be found at their respective web sites.

Agilent Ventures — www.agilentventures.com

Alloy Ventures — www.alloyventures.com

Latterell Venture Partners — www.lvpcapital.com

Versant Ventures — www.versantventures.com

The Vertical Group — www.vertical-group.com

About ForteBio, Inc.

ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification and characterization of proteinprotein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities provide greater value in applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.

Contact Information :
Winne Wan
President and CEO, ForteBio, Inc.
(650) 322-1360
wwan@fortebio.com

We use cookies to personalize content and improve your browsing experience.

We also use analytics & advertising services. To opt-out click for more information.